WET AGE RELATED MACULAR DEGENERATION
Clinical trials for WET AGE RELATED MACULAR DEGENERATION explained in plain language.
Never miss a new study
Get alerted when new WET AGE RELATED MACULAR DEGENERATION trials appear
Sign up with your email to follow new studies for WET AGE RELATED MACULAR DEGENERATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New eye implant could slash treatment shots for wet AMD
Disease control OngoingThis phase 3 study tests EYP-1901, a slow-release implant, against standard aflibercept injections in 400 people with wet AMD. The goal is to see if the implant can maintain or improve vision while reducing how often patients need eye injections over 2 years. Participants must ha…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 08:15 UTC
-
New hope for wet AMD: experimental drugs take on standard treatment in major trial
Disease control OngoingThis phase 3 study tests two new drugs (tarcocimab tedromer and tabirafusp tedromer) against a standard treatment (aflibercept) for wet age-related macular degeneration, a leading cause of vision loss. About 675 people with untreated wet AMD will receive one of the three treatmen…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: Kodiak Sciences Inc • Aim: Disease control
Last updated May 17, 2026 08:14 UTC
-
Could fewer eye injections work for wet AMD? new study tests shorter loading phase
Disease control OngoingThis study tests whether people with wet age-related macular degeneration (AMD) can safely extend the time between eye injections earlier than usual, skipping the standard three monthly loading doses. About 80 adults aged 50+ with active wet AMD will receive either aflibercept or…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: NA • Sponsor: Berner Augenklinik • Aim: Disease control
Last updated May 17, 2026 08:13 UTC
-
New eye drug could cut injection frequency for wet AMD patients
Disease control OngoingThis phase 3 study tests EYP-1901, a new eye injection that may last longer than current treatments for wet age-related macular degeneration (AMD). About 400 participants will receive either EYP-1901 or standard aflibercept injections. The goal is to see if EYP-1901 can maintain …
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE3 • Sponsor: EyePoint Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 08:00 UTC
-
One-Time gene therapy could free wet AMD patients from lifelong eye injections
Disease control OngoingThis study tests a one-time gene therapy called RGX-314 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The goal is to see if a single treatment can control the disease and reduce the need for repeated eye injections. About 671 adults a…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated May 12, 2026 13:41 UTC
-
Gene therapy for wet AMD: Long-Term safety check underway
Disease control OngoingThis study follows 23 people who received a single dose of ADVM-022 gene therapy for wet age-related macular degeneration (AMD) in an earlier trial. Researchers are monitoring long-term safety and how well the treatment controls vision loss and retinal swelling over time. The goa…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Sponsor: Adverum Biotechnologies, Inc. • Aim: Disease control
Last updated May 11, 2026 20:46 UTC
-
Eye drops could replace needles for wet AMD?
Disease control OngoingThis early-stage trial tests whether NT-101 eye drops can safely control wet age-related macular degeneration (AMD), a leading cause of vision loss. About 30 adults aged 50 and older with active wet AMD will use the drops for up to 8 weeks. The main goal is to check safety, but r…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Phase: PHASE1, PHASE2 • Sponsor: NexThera Co., Ltd. • Aim: Disease control
Last updated Apr 30, 2026 15:48 UTC
-
Eye-Tracking tech could revolutionize wet AMD detection
Diagnosis OngoingThis study evaluates a system called AVIGA that uses eye-tracking to detect central vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the system's results with standard tests like eye scans and vision charts. The goal is to see if…
Matched conditions: WET AGE RELATED MACULAR DEGENERATION
Sponsor: Tan Tock Seng Hospital • Aim: Diagnosis
Last updated May 17, 2026 08:00 UTC